Business
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2021 with Webcast and Conference Call Today at 4:30 p.m. ET
Reported Positive Data from a Phase 1b Study of EDP-514 in NUC-Suppressed Chronic Hepatitis B Virus (HBV) Patients Supporting Once Daily Dosing and
About this update from Enanta Pharmaceuticals, Inc.
[{"type":"text","content":"\n\nReported Positive Data from a Phase 1b Study of EDP-514 in NUC-Suppressed Chronic Hepatitis B Virus (HBV) Patients Supporting Once Daily Dosing and Combination Approach\n\n\nOn Track to Report Preliminary Data from a Phase 1b Study of EDP-514 in Viremic Chronic HBV Patients in Q2 2021 and to Initiate a Phase 1 Study of EDP-721 in Mid-2021\n\n\nIND-Enabling Studies of a Lead Oral Protease Inhibitor Specifically Designed for SARS-CoV-2 Expected to Begin in Q2 2021\n\n\nInitiated RSVPEDs, a Phase 2 Study of EDP-938 in Pediatric Patients with Respiratory Syncytial Virus (RSV) Infection\n\n\nRoyalty Revenue for the Quarter was $20 Million\n\n\nCash and Marketable Securities Totaled $400 Million at March 31, 2021\n\n\n WATERTOWN, Mass.--(BUSINESS WIRE)--\nEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today reported financial results for its fiscal second quarter ended March 31, 2021.\n\n“This quarter was marked by meaningful progress, particularly as we further our efforts to develop an all-oral regimen for chronic HBV patients,” said Jay R. Luly, Ph.D., President and Chief Executive Officer of Enanta Pharmaceuticals. “We are especially pleased with the safety, tolerability, pharmacokinetic, and HBV RNA data we announced today from our Phase 1b study in NUC-suppressed patients, which reinforces our belief in EDP-514’s potential to serve as the foundation of an oral combination treatment approach to achieve a functional cure in patients with HBV. We also remain on track for other key milestones in our HBV program later this quarter, including reporting preliminary data from our Phase 1b trial of EDP-514 in viremic chronic HBV patients and initiating a Phase 1 study of EDP-721, our novel HBV RNA destabilizer. Looking to the rest of our pipeline, we are excited to soon initiate IND-enabling studies of a lead oral protease inhibitor specifically designed to target SARS-CoV-2, with a goal of beginning a Phase 1 study in early 2022. Each milestone we achieve brings us closer to our vision of being a leader in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases.”\n\nFiscal Second Quarter Ended March 31, 2021 Financial Results\n\nTotal revenue for the three mont...